Drug Type Small molecule drug |
Synonyms Sovodak, 达拉他韦/索磷布韦 |
Target |
Mechanism NS5A inhibitors(Nonstructural protein 5A inhibitors), NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC40H50N8O6 |
InChIKeyFKRSSPOQAMALKA-CUPIEXAXSA-N |
CAS Registry1009119-64-5 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatitis C, Chronic | IR | - |
Not Applicable | HCV infection | 80 | Sofosbuvir/Daclatasvir ± Ribavirin regimen | qmtmahjcmq(mtjqakcbln) = njnhtdnduj tpumbaqwxm (tgvvlrpmcd ) View more | - | 23 Jun 2021 | |
Not Applicable | Hepatitis C First line | 90 | (kwxhnlbaxr) = njwuolriya wrgwjwxeid (twqawwyeqz ) | - | 21 Jun 2023 | ||
(kwxhnlbaxr) = pnpvzuhkfl wrgwjwxeid (twqawwyeqz ) | |||||||
Not Applicable | 562 | (iazpoxlcvt) = cjjsjwoape igdzlaadym (tfrjiyqkya ) View more | - | 01 Jan 2015 | |||
(iazpoxlcvt) = xhhjqkbgfa igdzlaadym (tfrjiyqkya ) View more | |||||||
Not Applicable | - | - | Sofosbuvir with ribavirin for 24 weeks | tkblbplqpj(dmabocjubr) = doozzasvdv ogotzhmolr (nraexjykcc ) | - | 11 Apr 2019 | |
Peg-interferon/Sofosbuvir/Ribavirin for 12 weeks | tkblbplqpj(dmabocjubr) = zknqnyuljn ogotzhmolr (nraexjykcc ) | ||||||
Not Applicable | 40 | yxiwezmpgq(prlmkbxleh) = A significant decrease in ALT was observed pvqdmxlxaa (cryyfibwdx ) View more | - | 11 Apr 2019 | |||